Neurocrine Biosciences has announced that FDA has granted breakthrough therapy designation for NBI-98854 (Vesicular Monoamine Transporter 2 inhibitor) drug in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1xKewL6
No comments:
Post a Comment